Trinucleotide Cap Analogs Blocking Unwanted Initiation for Translatable mRNA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing capped RNA molecules face limitations in intracellular stability and efficiency of in vitro transcription, leading to reduced translation yields and stability, particularly in applications like mRNA vaccines and immunotherapy.
Innovation Solution
Development of trinucleotide cap analogs that enhance capping efficiency, improve translation efficiencies, and increase intracellular stability, using modified structures with specific base combinations and linkages to prevent unwanted transcription initiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If dinucleotide cap analogs (mCAP) are used as transcription initiators, then capped RNA can be produced, but approximately 50% of the capped RNA is non-translatable due to unwanted transcription initiation from the 3'-OH group
Solution Approach 1:
The patent removes the problematic 3'-OH group functionality by replacing it with a modified base structure that cannot initiate transcription, while preserving the 5' cap structure necessary for translation. This extraction of the harmful transcription initiation capability from the cap analog resolves the contradiction between producing capped RNA and ensuring its translatability.
Solution Approach 2:
The invention modifies only the specific region of the cap analog that causes the problem (the 3' end with the 3'-OH group) while leaving the essential 5' cap structure intact. By applying local modification to eliminate transcription initiation capability at the 3' end, the patent maintains translation efficiency while preventing non-translatable RNA formation.
2Reliability
If modified cap analogs with blocked 3'-OH groups are used to prevent unwanted transcription, then translation efficiency improves, but transcription yield and intracellular stability remain limited
Solution Approach 1:
The patent changes the chemical parameters of the cap analog by introducing specific base modifications (such as 7-methylguanosine with additional methyl groups or modified ring structures) that alter the transcription and translation properties. These parameter changes enhance both transcription yield and intracellular stability while maintaining the translation efficiency improvement from the blocked 3'-OH group.
Solution Approach 2:
The invention creates a composite cap analog structure that combines multiple functional elements: the 5' cap structure for translation initiation, the blocked 3'-OH group for preventing unwanted transcription, and additional modified bases for enhanced stability and transcription efficiency. This composite structure resolves the contradiction between translation efficiency and transcription yield.
3Productivity
If standard capped RNA is used for in vitro transcription, then transcription can proceed, but intracellular stability of the mRNA is reduced
Solution Approach 1:
The patent modifies chemical parameters of the cap analog (such as adding methyl groups at positions 2 and 2' of the ribose, or modifying the base structure) to enhance resistance to nucleases and other degradation mechanisms in the intracellular environment. These parameter changes maintain transcription activity while significantly improving intracellular stability and duration of action.
Data Source
AI summary
This specification generally relates to trinucleotide RNA cap analogs, methods of use thereof, and kits comprising same. In particular, the trinucleotide cap analogs provided herein permit ready detection and/or isolation of capped RNA transcripts in vitro and translation of capped mRNAs in vivo.